NCT03919526View on ClinicalTrials.gov

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 11, 2019

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
MRD-positiveAcute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

anti-CD19/CD22 CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03919526 - Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL | Biotech Hunter | Biotech Hunter